Reference
Ku GY, et al. Durvalumab (D) and PET-directedchemoradiation (CRT) afterinduction FOLFOX for esophagealadenocarcinoma. Journal of Clinical Oncology 39 (Suppl.): abstr. 226, No. 3, Jan 2021. Available from: URL: http://doi.org/10.1200/JCO.2021.39.3_suppl.226 [abstract]
Rights and permissions
About this article
Cite this article
Antineoplastics. Reactions Weekly 1849, 50 (2021). https://doi.org/10.1007/s40278-021-93434-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-021-93434-5